Home » Australia’s TGA Announces End of EpiPen Shortage
Australia’s TGA Announces End of EpiPen Shortage
Australia’s Therapeutic Goods Administration declared that a shortage of EpiPen 300 mcg adrenaline auto-injectors has been resolved.
Alphapharm, doing business as Mylan Australia, confirmed that patient needs are currently being met now that there is a sufficient supply of the auto-injectors.
The supply shortage, caused by manufacturing delays at a Pfizer facility which produces the auto-injectors for Mylan, began in April 2018.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May